Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02111057 · ClinicalTrials.gov registry record
Perioperative Flare in RA: Characterization of Clinical and Biological Features
A clinical trial of Rheumatoid Arthritis, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- 162
- Enrollment target
- 1
- Study location
NCT02111057: Completed study of Rheumatoid Arthritis, sponsored by Hospital for Special Surgery, New York.
NCT02111057 is a study of Rheumatoid Arthritis that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 162 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02111057, a study of Rheumatoid Arthritis, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- 162 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers at the Hospital for Special Surgery are trying to learn more about post-operative rheumatoid arthritis flare (RA). This study hopes to understand RA flare after total joint replacement surgery and what the result of flaring is for patients over the 6 weeks post operation. Through this study we aim to describe rates, characteristics, and risk factors of RA flare within 6 weeks of total hip arthroplasty (THA) and total knee arthroplasty (TKA)
Primary Outcome
The primary outcome is the rate of RA flare within 6 weeks of surgery as measured by the Outcome Measures in Rheumatoid Arthritis Clinical Trials(OMERACT) flare questionnaire. For comparison, the rate of RA flare at 1 week post surgery is measured.
Conditions Studied
Study Locations (1)
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2013-10-16 |
| Est. Completion | 2017-05-09 |
What the finished NCT02111057 record still lists
NCT02111057 is an observational study that tracks outcomes without assigning an intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 0 interventions.
NCT02111057 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02111057 about?
NCT02111057 is a clinical study titled "Perioperative Flare in RA: Characterization of Clinical and Biological Features". Researchers at the Hospital for Special Surgery are trying to learn more about post-operative rheumatoid arthritis flare (RA). This study hopes to understand RA flare after total joint replacement surgery and what the result of flaring is for patients over the 6 weeks post operation. Through this s...
What is the current status of trial NCT02111057?
This trial is currently completed. The enrollment target is 162 participants. The study started on 2013-10-16. Estimated completion is 2017-05-09.
What conditions does trial NCT02111057 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
Who is sponsoring clinical trial NCT02111057?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02111057 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02111057's enrollment target sits among peer trials
162 93rd of 197 higher than 105 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI